Showing results (31-40 of 301) with videos related to
Sort By:
Pageof 31
Clinical Colorectal Cancer|May 16, 2020
Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution ExperienceFranklin Li, Gradon Nielsen, Andrea Baran, et al.Genes & Development|November 23, 2006
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancerNabeel Bardeesy, Kuang-Hung Cheng, Justin H Berger, et al.Cancer Research|January 24, 2012
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinomaMichael R O'Dell, Jing Li Huang, Christa L Whitney-Miller, et al.The Oncologist|December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingDarrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.Cancer|April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.Advances in Radiation Oncology|August 12, 2017
Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinomaMostafa Mohamed, Alan W Katz, Mohamedtaki A Tejani, et al.Human Pathology|February 2, 2024
SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma: Clinicopathologic and immunohistochemical studyIrene Y Chen, Mark G Ettel, Phoenix D Bell, et al.Cancer|June 22, 2010
The role of targeted agents in preoperative chemoradiation for rectal cancerRaymond C Wadlow, David P RyanCurrent Treatment Options in Oncology|August 13, 2013
Controversy and consensus on the management of patients with pseudomyxoma peritoneiJason E Faris, David P RyanPageof 31